News
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
VALBIOTIS SA: Valbiotis® strengthens its foothold in pharmacies with two strategic partnerships
VALBIOTIS SA: Valbiotis® strengthens its foothold in pharmacies with two strategic partnerships
VALBIOTIS SA: In anticipation of a change in regulations, Valbiotis® offers a scientifically proven alternative to red yeast rice for cholesterol management
VALBIOTIS SA: In anticipation of a change in regulations, Valbiotis® offers a scientifically proven alternative to red yeast rice for cholesterol management
VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211039390/en/
Evolution of Visual Acuity in the REFLECT Phase III
VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Correction of a release from 04.12.2025 17:56 CET/CEST - BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
Correction of a release from 04.12.2025 17:56 CET/CEST - BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
BILENDI: 2025 revenue as of 30 September: €64.5 million, up +42.9%
BILENDI: 2025 revenue as of 30 September: €64.5 million, up +42.9%
ROCTOOL: Postponement of publication of 2025 half-year results
ROCTOOL: Postponement of publication of 2025 half-year results
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
BILENDI: New record results in the first half of 2025 • Historic half-yearly EBITDA margin of 20.6 % (+1.9 pt) • Adjusted operating profit up +87 %
BILENDI: New record results in the first half of 2025 • Historic half-yearly EBITDA margin of 20.6 % (+1.9 pt) • Adjusted operating profit up +87 %
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
ROCTOOL: Live at K-Show: Roctool Slashes Cycle Times in High-Heat Molding Demonstrations
ROCTOOL: Live at K-Show: Roctool Slashes Cycle Times in High-Heat Molding Demonstrations